AMS IS THE INDUSTRY LEADER IN STRATEGIC INTELLIGENCE SOFTWARE FOR COMBATTING EMERGING HIGH-COST CLAIM ISSUES
What We Do:
AMS delivers crucial insight into catastrophic diagnoses, specialty pharmaceutical, and implant price transparency through clinically vetted, predictive financial analytics with near real-time data.
Who We Serve:
AMS serves multiple stakeholders in the medical claims payment chain, including commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.
WHO IS USING THE PREDICT SUITE
THE PREDICT SUITE
AMS’ Web-based directories that allow
clients to predict, evaluate and manage high dollar healthcare claims.
PREDICT
Predict costs and clinical treatments for high dollar diagnoses with an on demand decision support solution delivering in-depth clinical information, empirical insight and key financial analytics.
EVALUATE
Evaluate cost data, FDA approved indications, notable off-label usage, adult/pediatric dosing regimens, manufacturer rebates, specialty drug coding and price trends.
MANAGE
Manage highly inflated implant claims by leveraging detailed clinical and financial metrics with the only online, fully- transparent implant cost directory in the industry.
PREDICT SUITE MEMBERSHIP HAS ITS BENEFITS
100%
Reference Rate
Predict Suite Members willing + eager to connect with prospects
99%
Members
Retained
We have retained 99% of our members
13,000
Clinical/Financial Iterations
Including rules, off label + orphan drug uses, price benchmarks and CPT codes
100s
Weekly Hours
Saved
We have saved our clients and members 100s of weekly hours in research and underwriting
AMS Blog
-
Australian researchers develop 10-minute cancer test
December 5, 2018
Researchers in Australia have developed a 10-minute test that can detect the presence of cancer cells anywhere in the human body, according to a newly published study. The test was developed after researchers from the University of Queensland found that cancer forms a unique DNA structure when placed in water. The test works by identifying… Read More » -
The Food and Drug Administration has failed to ensure that drugs given prized rare-disease status meet the intent of a 35-year-old law, federal officials revealed in a report Friday. The Government Accountability Office, which spent more than a year investigating the FDA’s orphan drug program, said “challenges continue” in the program that was created to… Read More »